“You can just stop taking a GLP-1 once you reach your goal weight.”
What the evidence shows
In the STEP 1 trial extension, participants who stopped semaglutide regained about two-thirds of the weight they had lost within a year, and much of the cardiometabolic improvement reversed too. GLP-1s treat obesity as a chronic condition: when the medicine stops, the biology that drove the weight tends to reassert itself. This is one of the most consistent findings in the field.
What we still don’t know
Not everyone regains at the same rate, and strategies to make stopping work better — dose tapering, switching to a maintenance approach, intensive lifestyle support — are being studied but aren't settled. Whether some people can maintain off-drug, and who they are, isn't well predicted yet.
Why the claim misleads
"Just stop at goal" frames the medicine like an antibiotic — a course you finish. The evidence shows it's more like treatment for blood pressure: it works while you take it. Stopping is a legitimate choice, but it's a planned decision with your clinician about how to hold the results, not a finish line.
Graded by The Peptide Era · evidence, not hype